Efficacy and safety of raltitrexed plus S-1 versus regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study

Zhou, YW; Wang, JL; Li, QF; He, YL; Li, LJ; Liu, RZ; Chen, Y; Zhang, S; Qiu, M; Liu, JY

Liu, JY (通讯作者)，Sichuan Univ, West China Hosp, Ctr Canc, Dept Biotherapy, 37 Guoxue Xiang St, Chengdu 610041, Sichuan, Peoples R China.;Qiu, M (通讯作者)，Sichuan Univ, West China Hosp, Ctr Canc, Dept Abdominal Oncol, 37 Guoxue Xiang St, Chengdu 610041, Peoples R China.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022; 15 ():

Abstract

Background: Raltitrexed plus S-1 (RS) and regorafenib both showed considerable efficacy for metastatic colorectal cancer (mCRC) patients. This study a......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索